CV Check Ltd
CV Check Ltd (ASX: CV1) is a leading online integrated screening and verification company which offers check products to employers, industry associations and individual customers through the CVCheck brand on its proprietary web-based platform cvcheck.com. With a market cap of ~AUD 39.58 million and 272.98 million outstanding shares, the CV1 stock last traded today (on 19 June 2019) at AUD 0.170, edging up 17.241% by AUD 0.025 with ~ 717,980 shares traded.
The company informed today that its Business-to-Business segment (B2B) is consistently delivering solid growth in Annualised Recurring Revenue (ARR) with YTD FY19 ARR already exceeding $9 million. In May 2019 alone, around 10 new Large Enterprise customer engagements were secured including G4S Australia Limited, Kennards Hire, Baptistcare, Bluefin Resources Pty Ltd, National Hearing Care Australia, two additional Singtel Optus Pty Limited satellite divisions, and others.
Source: Investor Presentation
CV1 acquired its New Zealand business assets on 1 July 2016. After adjusting for the acquired NZ FY16 revenue of AUD 1.1 million, the compound annual growth rate (CAGR) of ARR for the 3-years to FY19 YTD is ~32%. As per the company, the organic growth is being propelled by new large enterprise customers, tender wins and higher average revenue per account.
Family Zone Cyber Safety Limited
Technology company, Family Zone Cyber Safety Limited (ASX: FZO), based in West Perth, Australia, develops cyber safety products including a cloud-based Family Zone Platform; Family Zone Box to protect connected devices at home; and Family Zone App. With a market capitalisation of AUD 27.08 million and ~ 200.63 million shares outstanding to date, the FZO stock closed flat (on 19 June 2019) at AUD 0.135. Around 1, 300, 674 million had exchanged the hands of the shareholders.
Today, Family Zone updated the market on its developing relationship with Google.
Source: Company’s announcement dated 19 June’19
The company has been closely working with Google Cloud since early CY2019 to transform back-end services to support global delivery and scale. On the back of this work, Family Zone has recently joined the Technology Partner Program as a Google Cloud Partner and a Google for Education Partner.
A gradual deeper integration between Family Zone’s Education Solutions and Google’s G Suite for Education and Chromebook platforms, would enable the company to offer schools greater visibility and control over security, streamlined student and class administration and also the ability to drive effective digital citizenship programs in both BYOD and 1:1 environments.
On 21 May 2019, the company announced that it has crossed 100,000 paying accounts (subscribers) driven by growth across all channels at the end of April 2019.
Source: Company’s announcement dated 21 May’19
Red Sky Energy Limited
Oil and gas development company, Red Sky Energy Limited (ASX: ROG) has 100% highly prospective projects located in Australia’s Cooper Basin, with initial development targets being the Flax Project and the Yarrow Project. With a market capitalisation of AUD 2.51 million and approximately 1.25 billion outstanding shares, the ROG stock last traded today (19 June 2019) at AUD 0.003, zooming up 50% by AUD 0.001 with ~ 6,808,491 shares traded.
Today, the company has released the results of the recently completed strategic review on its 100% owned Flax Oil and Gas Project, which contains a 2C contingent resource of 9.9m barrels of oil and 24 BCF of natural gas (infrastructure in place) and six production wells that produced ~180k barrels of oil between 2009 and 2015.
Red Sky plans to develop Flax in two phases. Phase 1 would be a low capex, quick revenue starter project including external review of in place infrastructure, signing offtake contracts for FOB oil delivery and opening existing six wells. Under Phase II, the substantial 2C Contingent Resource of 9.9 million barrels of oil would be targeted, that could potentially be increased by using Enhanced Oil Recovery (EOR) techniques.
At the current Australian dollar oil price of around AUD 100 per barrel, revenues (see figure below) from enhanced oil recovery could be very significant.
Source: Company’s Report
Murdoch-based Orthocell Limited (ASX: OCC) is a world renowned regenerative medicine company engaged in the development and commercialisation of cell therapies to expedite the repair of soft tissue injuries and promote movement for patients. It has an advanced product portfolio comprising- autologous tenocyte implantation Ortho-ATI®; collagen medical device CelGro®; and autologous chondrocyte implantation, Ortho-ACI®. With a market cap of ~AUD 66.54 million and 152.97 million shares outstanding, the OCC stock price settled the day’s (19 June 2019) market session at AUD 0.495, climbing up 12.644% with ~ 13.81 million shares traded.
Today, Orthocell has announced to the market that all (10) patients have successfully completed the CelGro® single-stage dental implant Marketing Study, designed to assess effectiveness and predictability in accelerating treatment timeframes. The Study results further validate CelGro® superiority as a medical device for bone and soft tissue repair, as the patients generated enough new bone to stabilise their implants and complete treatment in approximately four months, that is almost half the time of the usual two-stage treatment (see figure below).
Comparison of two implant procedures, Source: Company’s Report
Dental implants are an effective and rapidly growing area of orthodontic treatment. The addressable market for CelGro® has been forecasted to be over USD 900 million per annum.
West Perth, Australia-based medical technology company HeraMed Limited (ASX: HMD), established in 2011, is engaged in the development and commercialisation of pregnancy monitoring solutions for home and professional use across Europe, Israel and Australia. HeraMed is presently focussed to rapidly commercialise HeraBEAT, a smart medical grade ultrasound monitoring device and has secured approvals from key regulatory bodies -AMAR (Israel), CE (Europe) and TGA (Australia) so far.
Source: Company Presentation May 2019
With a market capitalisation of AUD 18.82 million and ~ 87.53 million outstanding shares, the HMD stock settled the day’s trading at AUD 0.210, down 2.33% with ~ 111,436 shares traded. Besides, the stock has delivered positive return yields of 16.22% for the last six months and 22.86% YTD.
HeraMed updated the market today about the Australian business to consumer (B2C) launch of its medical grade foetal heart rate monitor, HeraBEAT. The highlights include a dedicated Australian B2C website and marketing campaign to be launched on 26 June 2019 across multiple channels to drive product uptake and awareness.
HeraMED, Dale Group International and Meerkats have developed a best in class marketing strategy and Meerkats will receive a pre-negotiated commission from Australian distributor Dale Group for each device sold.
ImpediMed Limited (ASX: IPD) develops and sells non-invasive medical devices for diagnosing and monitoring human disorders and diseases, particularly in cancer survivors. It has operations in the US (San Diego), Australia (Brisbane) and Europe (Greece). ImpediMed’s market capitalisation stands at ~AUD 39.88 million and it has 379.8 million outstanding shares on the ASX. The IPD stock closed today’s trading session, at the last price of AUD 0.115, climbing up 9.52% by AUD 0.010.
The company released its Investor Presentation today touching upon various aspects of the business and ongoing activities. The investment highlights and the trend of its Technology Adoption through direct sales channels are illustrated below.
Source: Investor Presentation
The company informed that its SaaS Business Model was now well established in Lymphoedema, a leading post-surgical complication for many cancer patients, and accelerating revenues on the back of aggressively driven National Lymphoedema Prevention Program in new key centres and build out in existing centres, targeting existing key customers for expanded patient testing, expanding indications at top cancer centres, educational seminars promoting awareness of the technology, continued clinical and economic publications etc.
Source: Company’s Report
Also, ImpediMed is well positioned to capitalise on lymphoedema prevention.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.